1. Show article details.

    FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

    GlobeNewswire – 7:00 AM ET 01/04/2022

    FibroGen, Inc. (FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

  2. Show article details.

    BRIEF-Fibrogen Exercises Exclusive License Option For Hifibio'S CCR8 Program

    Reuters – 8:29 AM ET 12/20/2021

    FibroGen Inc (FGEN): * FIBROGEN EXERCISES EXCLUSIVE LICENSE OPTION FOR HIFIBIO'S CCR8 PROGRAM. * FibroGen Inc (FGEN) - HIFIBIO TO RECEIVE $35 MILLION OPTION EXERCISE PAYMENT, POTENTIAL MILESTONES AND ROYALTIES. * FibroGen Inc (FGEN) - HIFIBIO WILL ALSO BE ELIGIBLE TO RECEIVE ROYALTIES BASED UPON NET SALES. * FibroGen Inc (FGEN) - DEVELOPMENT CANDIDATE IS EXPECTED TO ENTER CLINICAL DEVELOPMENT IN 2023.

  3. Show article details.

    FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

    GlobeNewswire – 8:00 AM ET 12/20/2021

    FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, today announced an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s ...

  4. Show article details.

    BRIEF-FibroGen Posts Q3 EPS Of $0.54

    Reuters – 4:51 PM ET 11/09/2021

    FibroGen Inc (FGEN): * FIBROGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS. * Q3 EARNINGS PER SHARE $0.54. * Q3 REVENUE $156 MILLION. * ESTIMATE OUR 2021 ENDING BALANCE OF CASH, CASH EQUIVALENTS, INVESTMENTS, AND ACCOUNTS RECEIVABLE TO BE IN RANGE OF $580-610 MILLION. * Q3 REVENUE VIEW $143.5 MILLION -- REFINITIV IBES DATA.

  5. Show article details.

    FibroGen Reports Third Quarter 2021 Financial Results

    GlobeNewswire – 4:01 PM ET 11/09/2021

    SAN FRANCISCO, Nov. 09, 2021 -- FibroGen (FGEN), Inc. today reported financial results for the third quarter 2021 and provided an update on the Company’s recent developments. “We and our partner Astellas are excited to be making Evrenzo available to patients in Europe,” said Enrique Conterno, Chief Executive Officer, FibroGen.

  6. Show article details.

    GSK says anaemia drug shows positive safety profile

    Reuters – 1:30 PM ET 11/05/2021

    GlaxoSmithKline said its anaemia pill for patients with kidney disease was shown to have about the same side effect risk as the current standard treatment in two important patient groups, a key advantage in a tight race with rival drug developers.

  7. Show article details.

    FibroGen to Present at Upcoming Investor Conferences

    GlobeNewswire – 7:00 AM ET 11/02/2021

    FibroGen, Inc. (FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences: An audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

  8. Show article details.

    FibroGen to Report Third Quarter 2021 Financial Results

    GlobeNewswire – 7:00 AM ET 10/26/2021

    FibroGen, Inc. (FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen (FGEN) website at https://fibrogen.gcs-web.com/events-and-presentations/events. Dial-In InformationLive: 658-9081Live: 563-8732Confirmation number: 1747879.

  9. Show article details.

    FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

    GlobeNewswire – 7:00 AM ET 10/25/2021

    FibroGen, Inc. (FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021. The accepted abstracts are now available on the ASN website at https://bit.ly/3FTP53Z.

  10. Show article details.

    FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

    GlobeNewswire – 7:00 AM ET 08/25/2021

    FibroGen, Inc. (FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of chemotherapy-induced anemia.

  11. Show article details.

    Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

    GlobeNewswire – 7:35 PM ET 08/19/2021

    Astellas Pharma Inc. and FibroGen, Inc. (FGEN) today announced that the European Commission has approved EVRENZO™  for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.

  12. Show article details.

    FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

    GlobeNewswire – 7:00 AM ET 08/16/2021

    FibroGen, Inc. (FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. “On behalf of the board, shareholders, and our employees, I want to thank Pat for his contributions as Chief Financial Officer and dedicated service over the past 21 years,” said Enrique Conterno, Chief Executive Officer, FibroGen.

  13. Show article details.

    FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

    GlobeNewswire – 7:00 AM ET 08/11/2021

    FibroGen (FGEN), Inc.  today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease. The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission.

  14. Show article details.

    FibroGen Reports Second Quarter 2021 Financial Results

    GlobeNewswire – 4:01 PM ET 08/09/2021

    • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis.

Page:

Today's and Upcoming Events

  • Feb
    28

    FGEN to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    09

    FGEN announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.